Zolpidem use and risk of suicide: A systematic review and
meta-analysis

J 2022

Zolpidem use and risk of suicide: A systematic review and meta-analysis

KHAN, Hiba, Aakriti GARG, Yasmeen YASMEEN, Nidhi B. AGARWAL, Deepak Kumar YADAV et. al.

Základní údaje

Originální název

Zolpidem use and risk of suicide: A systematic review and meta-analysis

Autoři

KHAN, Hiba, Aakriti GARG, Yasmeen YASMEEN, Nidhi B. AGARWAL, Deepak Kumar YADAV, Mohd ASHIF KHAN a Mohammad Salman HUSSAIN (356 Indie, domácí)

Vydání

Psychiatry Research, CLARE, ELSEVIER IRELAND LTD, 2022, 0165-1781

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30215 Psychiatry

Stát vydavatele

Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 11.300

Kód RIV

RIV/00216224:14110/22:00126537

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.psychres.2022.114777

UT WoS

000862817400004

Klíčová slova anglicky

Death; Epidemiology; Insomnia; Systematic review; Meta-analysis; Suicide; Zolpidem

Štítky

14119612, 14119613, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 1. 2023 14:31, Mgr. Tereza Miškechová

Anotace

V originále

Introduction Zolpidem is one of the most commonly prescribed nonbenzodiazepine hypnotic drugs for insomnia. Published epidemiological studies linked zolpidem with the risk of suicide. However, to date, no meta-analysis investigated this association. Hence, we systematically reviewed and meta-analysed the current evidence from real-world studies reporting the risk of suicide with the use of zolpidem. Methods Medline (Ovid), Embase (Ovid), and PsycINFO databases were searched from inception till June 2021 for real-world evidence studies reporting the risk of suicide with the use of zolpidem. The quality assessment of included studies was assessed using the New-Castle Ottawa Scale (NOS). Random-effect meta-analysis was performed using a generic inverse variance method. Results This meta-analysis was based on four studies with 344,753 participants, of which 42,279 were zolpidem users. The methodological quality of all the included studies was of high quality. A significantly increased risk of suicide or suicide attempt was found in zolpidem users compared to non-users, with a pooled relative risk of 1.88 (95% CI: 1.54 – 2.30). Furthermore, an increased risk of suicidal death was observed in zolpidem users compared to non-users, with a pooled relative risk of 1.82 (95% CI: 1.43 – 2.30). Dose-response analysis also revealed a significantly increased risk of suicide in patients receiving ≥ 180cDDD (cumulative defined daily doses) of zolpidem (124 times), followed by 90–179cDDD (113 times) and <90cDDD (93 times) of zolpidem compared to non-users. Conclusion In conclusion, zolpidem use was associated with an increased risk of suicide or suicide attempt and suicidal death. Therefore, careful prescribing practices must be followed by considering the risk-benefit profile.

Návaznosti

EF18_053/0016952, projekt VaV

Název: Postdoc2MUNI

Citovat

KHAN, Hiba, Aakriti GARG, Yasmeen YASMEEN, Nidhi B. AGARWAL, Deepak Kumar YADAV, Mohd ASHIF KHAN a Mohammad Salman HUSSAIN. Zolpidem use and risk of suicide: A systematic review and meta-analysis. Psychiatry Research. CLARE: ELSEVIER IRELAND LTD, 2022, roč. 316, October 2022, s. 1-8. ISSN 0165-1781. Dostupné z: https://dx.doi.org/10.1016/j.psychres.2022.114777.

@article{2213957,
   author = {Khan, Hiba and Garg, Aakriti and Yasmeen, Yasmeen and Agarwal, Nidhi B. and Yadav, Deepak Kumar and Ashif Khan, Mohd and Hussain, Mohammad Salman},
   article_location = {CLARE},
   article_number = {October 2022},
   doi = {http://dx.doi.org/10.1016/j.psychres.2022.114777},
   keywords = {Death; Epidemiology; Insomnia; Systematic review; Meta-analysis; Suicide; Zolpidem},
   language = {eng},
   issn = {0165-1781},
   journal = {Psychiatry Research},
   title = {Zolpidem use and risk of suicide: A systematic review and meta-analysis},
   url = {https://www.sciencedirect.com/science/article/pii/S0165178122003717},
   volume = {316},
   year = {2022}
}

TY  - JOUR
ID  - 2213957
AU  - Khan, Hiba - Garg, Aakriti - Yasmeen, Yasmeen - Agarwal, Nidhi B. - Yadav, Deepak Kumar - Ashif Khan, Mohd - Hussain, Mohammad Salman
PY  - 2022
TI  - Zolpidem use and risk of suicide: A systematic review and meta-analysis
JF  - Psychiatry Research
VL  - 316
IS  - October 2022
SP  - 1-8
EP  - 1-8
PB  - ELSEVIER IRELAND LTD
SN  - 01651781
KW  - Death
KW  - Epidemiology
KW  - Insomnia
KW  - Systematic review
KW  - Meta-analysis
KW  - Suicide
KW  - Zolpidem
UR  - https://www.sciencedirect.com/science/article/pii/S0165178122003717
N2  - Introduction Zolpidem is one of the most commonly prescribed nonbenzodiazepine hypnotic drugs for insomnia. Published epidemiological studies linked zolpidem with the risk of suicide. However, to date, no meta-analysis investigated this association. Hence, we systematically reviewed and meta-analysed the current evidence from real-world studies reporting the risk of suicide with the use of zolpidem. Methods Medline (Ovid), Embase (Ovid), and PsycINFO databases were searched from inception till June 2021 for real-world evidence studies reporting the risk of suicide with the use of zolpidem. The quality assessment of included studies was assessed using the New-Castle Ottawa Scale (NOS). Random-effect meta-analysis was performed using a generic inverse variance method. Results This meta-analysis was based on four studies with 344,753 participants, of which 42,279 were zolpidem users. The methodological quality of all the included studies was of high quality. A significantly increased risk of suicide or suicide attempt was found in zolpidem users compared to non-users, with a pooled relative risk of 1.88 (95% CI: 1.54 – 2.30). Furthermore, an increased risk of suicidal death was observed in zolpidem users compared to non-users, with a pooled relative risk of 1.82 (95% CI: 1.43 – 2.30). Dose-response analysis also revealed a significantly increased risk of suicide in patients receiving ≥ 180cDDD (cumulative defined daily doses) of zolpidem (124 times), followed by 90–179cDDD (113 times) and <90cDDD (93 times) of zolpidem compared to non-users. Conclusion In conclusion, zolpidem use was associated with an increased risk of suicide or suicide attempt and suicidal death. Therefore, careful prescribing practices must be followed by considering the risk-benefit profile.
ER  -

KHAN, Hiba, Aakriti GARG, Yasmeen YASMEEN, Nidhi B. AGARWAL, Deepak Kumar YADAV, Mohd ASHIF KHAN a Mohammad Salman HUSSAIN. Zolpidem use and risk of suicide: A systematic review and meta-analysis. \textit{Psychiatry Research}. CLARE: ELSEVIER IRELAND LTD, 2022, roč.~316, October 2022, s.~1-8. ISSN~0165-1781. Dostupné z: https://dx.doi.org/10.1016/j.psychres.2022.114777.

Podrobný výpis o publikaci